Sanket Shah
Medical · Roseville, CANPI 1255778353
Payments from drug & device makers
Across 124 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$307
- AstraZeneca$269
- Dexcom, Inc.$204
- Novo Nordisk$199
- Sanofi-aventis U.S. LLC$192
- Zealand Pharma US, Inc.$150
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $307 |
| AstraZeneca(2 entities) | 14 | $269 |
| Dexcom, Inc. | 7 | $204 |
| Novo Nordisk | 6 | $199 |
| Sanofi-aventis U.S. LLC | 14 | $192 |
| Zealand Pharma US, Inc. | 7 | $150 |
| Amgen(2 entities) | 7 | $145 |
| Mannkind Corporation | 6 | $143 |
| AbbVie | 9 | $129 |
| Ascensia Diabetes Care US Inc. | 1 | $120 |
| Lilly USA, LLC | 7 | $107 |
| Merck | 5 | $91 |
| Boehringer Ingelheim | 5 | $90 |
| Amarin Pharma, Inc. | 4 | $75 |
| Vivus LLC | 5 | $62 |
| IBSA Pharma Inc. | 3 | $45 |
| Acerus Pharmaceuticals Corporation | 2 | $33 |
| Insulet Corporation | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Pfizer | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,586 in reported general payments places this provider in the 75th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 210 | $217,551 |
| JardianceEmpagliflozin | 171 | $137,233 |
| OzempicSemaglutide | 118 | $123,956 |
| TrulicityDulaglutide | 102 | $109,491 |
| AfrezzaInsulin Regular, Human | 13 | $45,318 |
| ForteoTeriparatide | 11 | $43,348 |
| TymlosAbaloparatide | 11 | $33,305 |
| FarxigaDapagliflozin Propanediol | 33 | $26,247 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 63 | $24,835 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $18,923 |
| VascepaIcosapent Ethyl | 25 | $18,250 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $15,002 |
| Humalog Kwikpen U-100Insulin Lispro | 69 | $14,921 |
| JanuviaSitagliptin Phosphate | 19 | $14,443 |
| TradjentaLinagliptin | 18 | $11,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $107 | $370,391323 claims |
| Boehringer IngelheimJardiance, Tradjenta | $90 | $148,275189 claims |
| Novo NordiskOzempic | $199 | $123,956118 claims |
| Mannkind CorporationAfrezza | $143 | $45,31813 claims |
| Radius Health, Inc.Tymlos | $15 | $33,30511 claims |
| AstraZenecaFarxiga, Crestor | $269 | $29,77746 claims |
| MerckJanuvia | $91 | $14,44319 claims |
| AbbVieSynthroid | $129 | $1,35918 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,114103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 medical providers in California.
Other medical in Roseville
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.